SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Studies suggest these agents may improve cardiovascular outcomes, enhance renal function, and offer promising benefits in managing NAFLD, thus broadening their therapeutic scope.[34–36] SGLT2 inhibitors, originally developed for glucose control in T2DM, have demonstrated significant therapeutic benefits beyond diabetes management.